Journal Article

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma

Chang, Gaomei, Klener, Pavel, Ilieva, Kristina, Horna, Pedro, Yousefi, Kasra, Landgraf, Karin, Kurz, Katrin S., Ott, German, Berning, Philipp, Grau, Michael, Khandanpour, Cyrus, Augsberger, Christian, Patra-Kneuer, Maria, Zapukhlyak, Myroslav, Endell, Jan, Heitmüller, Christina, Lenz, Georg, Schanzer, Jürgen, Steidl, Stefan, Xu, Wendan, Mangelberger-Eberl, Doris

2023

Overview

BackgroundDespite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel therapies are urgently needed. As the anti-CD20 antibody rituximab and the CD19-targeting antibody tafasitamab share distinct modes of actions, we investigated if dual-targeting of aggressive lymphoma B-cells by combining rituximab and tafasitamab might increase cytotoxic effects.MethodsAntibody single and combination efficacy was determined investigating different modes of action including direct cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) in in vitro and in vivo models of aggressive B-cell lymphoma comprising diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).ResultsThree different sensitivity profiles to antibody monotherapy or combination treatment were observed in in vitro models: while 1/11 cell lines was primarily sensitive to tafasitamab and 2/11 to rituximab, the combination resulted in enhanced cell death in 8/11 cell lines in at least one mode of action. Treatment with either antibody or the combination resulted in decreased expression of the oncogenic transcription factor MYC and inhibition of AKT signaling, which mirrored the cell line-specific sensitivities to direct cytotoxicity. At last, the combination resulted in a synergistic survival benefit in a PBMC-humanized Ramos NOD/SCID mouse model.ConclusionThis study demonstrates that the combination of tafasitamab and rituximab improves efficacy compared to single-agent treatments in models of aggressive B-cell lymphoma in vitro and in vivo .

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: AKT protein / Animal models / Antibodies / antibody therapy / Antibody-dependent cell-mediated cytotoxicity / Antigens / B-cell lymphoma / Burkitt's lymphoma / CD19 / CD19 antigen / CD20 / CD20 antigen / Cell culture / Cell death / Cells / Cloning / Cytotoxicity / FDA approval / Flow cytometry / Gene expression / Immunology / Immunotherapy / Lymphocytes B / Lymphoma / Myc protein / Patients / Peripheral blood mononuclear cells / Phagocytosis / Rituximab / tafasitamab / tumor immunology